Get started
Author

Karl‐Josef Kallen

Observed names: K J Kallen, K. J. Kallen, K. Kallen, K.-J. Kallen, K.J. Kallen, KARL-JOSEF KALLEN, KJ Kallen, Kallen Karl-Josef, Kallen, K. J., Kallen, Karl-Josef, Karl-Josef KALLEN, Karl-Josef Kallen, Karl-josef Kallen
Institution: CureVac (Germany)
Observed institutions: Merck KGaA, Darmstadt (Germany), GlaxoSmithKline (United Kingdom), Johannes Gutenberg University Mainz, Christian-Albrechts-Universität zu Kiel, University Medical Center of the Johannes Gutenberg University Mainz, CureVac (Germany), Merck Healthcare KGaA, Darmstadt (Germany), University College London, RWTH Aachen University, KU Leuven
OpenAlex ID: A5001797354
The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion
2003 · Christian Hundhausen, Dominika Misztela, et al. · Blood · 730
Developing mRNA-vaccine technologies
2012 · Thomas Schlake, Andreas Thess, et al. · RNA Biology · 636
PDF
A bioactive designer cytokine for human hematopoietic progenitor cell expansion
1997 · Martina Fischer, Jutta Goldschmitt, et al. · Nature Biotechnology · 532
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection
2012 · Benjamin Petsch, Margit Schnee, et al. · Nature Biotechnology · 464
The Transmembrane CXC-Chemokine Ligand 16 Is Induced by IFN-γ and TNF-α and Shed by the Activity of the Disintegrin-Like Metalloproteinase ADAM10
2004 · Soeren Abel, Christian Hundhausen, et al. · The Journal of Immunology · 440
Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE)
2003 · Vance Matthews, Björn Schuster, et al. · Journal of Biological Chemistry · 404
Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity
2010 · Mariola Fotin-Mleczek, Katharina M. Duchardt, et al. · Journal of Immunotherapy · 340
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
2015 · Hubert Kübler, Birgit Scheel, et al. · Journal for ImmunoTherapy of Cancer · 289
PDF
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
2019 · Alexandros Papachristofilou, Madeleine M. Hipp, et al. · Journal for ImmunoTherapy of Cancer · 233
PDF
A novel, disruptive vaccination technology
2013 · Karl-Josef Kallen, Regina Heidenreich, et al. · Human Vaccines & Immunotherapeutics · 224
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
2019 · Martin Sebastian, Andreas Schröder, et al. · Cancer Immunology Immunotherapy · 212
The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases
2002 · Karl-Josef Kallen · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · 205
PDF
The Interleukin-6 Cytokine System Regulates Epidermal Permeability Barrier Homeostasis
2004 · Xu-Ping Wang, Michael Schunck, et al. · Journal of Investigative Dermatology · 186
PDF
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
2014 · Martin Sebastian, Alexandros Papachristofilou, et al. · BMC Cancer · 143
PDF
Signaling of Human Ciliary Neurotrophic Factor (CNTF) Revisited
2003 · Björn Schuster, Marina Kovaleva, et al. · Journal of Biological Chemistry · 142
PDF
A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs
2013 · Karl-Josef Kallen, Andreas Theß · Therapeutic Advances in Vaccines · 122
PDF
Depletion of Cellular Cholesterol and Lipid Rafts Increases Shedding of CD30
2004 · Bastian von Tresckow, Karl-Josef Kallen, et al. · The Journal of Immunology · 117
IL-6 Type Cytokine Receptor Complexes: Hexamer, Tetramer or Both?
1999 · J. Grötzinger, T. Kernebeck, et al. · Biological Chemistry · 111
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
2012 · Mariola Fotin‐Mleczek, Kai Zanzinger, et al. · The Journal of Gene Medicine · 103
PDF
Receptor Recognition Sites of Cytokines Are Organized as Exchangeable Modules
1999 · Karl-Josef Kallen, Joachim Grötzinger, et al. · Journal of Biological Chemistry · 103
PDF
Murine Liver Antigen Presenting Cells Control Suppressor Activity of CD4+CD25+ Regulatory T Cells *
2005 · Christiane Wiegard, Christian Frenzel, et al. · Hepatology · 99
PDF
Lack of gp130 expression in hepatocytes promotes liver injury1 1K.L.S. and T.W. contributed equally to this work.
2003 · Konrad L StreetZ, Torsten Wüstefeld, et al. · Gastroenterology · 94
Dynamics of the gp130 cytokine complex: A model for assembly on the cellular membrane
2005 · Andreas Schroers, Oliver Hecht, et al. · Protein Science · 81
A novel RNA‐based adjuvant combines strong immunostimulatory capacities with a favorable safety profile
2014 · Regina Heidenreich, Edith Jasny, et al. · International Journal of Cancer · 80
IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier
2008 · Ralf A. Linker, Fred Lühder, et al. · Journal of Neuroimmunology · 74
Works count: 95
Citation count: 7,194
H-index: 37
I10-index: 52
Year
Topic
Type